Cash Flow from Investing Activities: The total change in cash resulting from a company's investments.
BioNexus Gene Lab Corp. (BGLC) had Cash Flow from Investing Activities of $0.94M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$0.48M |
|
$-1.04M |
|
$0.49M |
|
$-0.00M |
|
$1.52M |
|
$-1.03M |
|
$-0.00M |
|
$-1.04M |
|
$-1.04M |
|
$-1.04M |
|
$-1.04M |
|
$-1.04M |
|
$-1.04M |
|
$-1.02M |
|
$-0.98M |
|
1.86M |
|
1.86M |
|
$-0.83 |
|
$-0.83 |
|
| Balance Sheet Financials | |
$5.45M |
|
$1.60M |
|
$3.80M |
|
$9.25M |
|
$0.52M |
|
-- |
|
$0.12M |
|
$0.64M |
|
$8.61M |
|
$8.61M |
|
$8.61M |
|
2.42M |
|
| Cash Flow Statement Financials | |
$-1.84M |
|
|
Cash Flow from Investing Activities |
$0.94M |
$0.30M |
|
$2.89M |
|
$2.49M |
|
$-0.40M |
|
$0.79M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.46 |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-0.82% |
|
-213.50% |
|
-211.48% |
|
-- |
|
-214.18% |
|
-214.18% |
|
$-1.88M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
0.72 |
|
0.75 |
|
120.74 |
|
-12.03% |
|
-12.03% |
|
-11.20% |
|
-12.03% |
|
$3.56 |
|
$-1.01 |
|
$-0.99 |
|